Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.
Pfizer Takes 3% Stake In Sosei On Back Of Heptares GPCR Deal
Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.
More from Neurological
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.